Cingulate Inc. shares surged 30.7% amid strong investor interest in its ADHD treatment technology. Trading volume was high, with 3.297 million shares traded, reflecting growing market attention. Don’t ...

CTx-1301 is a once-daily, multi-core tablet utilizing Cingulate’s proprietary Precision Timed Release™ (PTR™) platform to deliver three precisely timed releases of dexmethylphenidate across the day.

The private placement gives a Boston investment firm two board seats as long as it maintains at least 15% ownership.

Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Kansas City, Kansas, company ...

Cingulate has posted pharmacokinetic data from an early-phase clinical trial of its triple-release anxiety drug candidate, providing itself with a platform to support development of a planned ...

KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to ...

Cingulate Inc. completes FDA Pre-NDA meeting for ADHD drug CTx-1301 and secures $3 million grant for anxiety treatment CTx-2103. Cingulate Inc. announced the successful completion of a Pre-NDA meeting ...

Editor's Note: Cingulate had filed a FORM S-1 with the SEC on March 10. The filing could have been a reason for the stock movement pre-market on March 13, rather than the commercialization agreement.

Retail chatter around Cingulate picked up on Tuesday after Roth Capital Partners raised its price target to $17 from $10 and reaffirmed a ‘Buy’ rating. Cingulate Inc.’s stock snapped a two-day losing ...